Immodulon Therapeutics Ltd
ImmunoModulon is a biotechnology company focused on developing innovative immunomodulatory therapies. The company is engaged in research and development activities related to immune checkpoint inhibitors, orphan drug designations, and novel immunomodulators for diseases such as tuberculosis and pancreatic cancer. They aim to advance medical science through their scientific advisory board, patents, and strategic appointments.
Industries
biotechnology
oncology
therapeutics
Nr. of Employees
small (1-50)
Immodulon Therapeutics Ltd
Products
Investigational immunomodulatory therapeutic (candidate with orphan designation for pancreatic cancer)
Investigational immunomodulatory therapeutic candidate reported on the site as having received orphan drug designation for pancreatic cancer.
Investigational immunomodulatory therapeutic (candidate associated with academic research)
Investigational candidate described in the context of collaborative research with an academic institution.
Investigational immunomodulatory therapeutic (candidate with orphan designation for pancreatic cancer)
Investigational immunomodulatory therapeutic candidate reported on the site as having received orphan drug designation for pancreatic cancer.
Investigational immunomodulatory therapeutic (candidate associated with academic research)
Investigational candidate described in the context of collaborative research with an academic institution.
Expertise Areas
- Clinical trial management
- Regulatory affairs (orphan drug designation and patent interactions)
- Immunotherapy research
- Mycobacteria-based immunomodulation research
Key Technologies
- Immunomodulatory therapeutics
- Combination immunotherapy with immune checkpoint inhibitors
- Mycobacteria-derived immunomodulation
- Preclinical immunology research